Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor, STRN, Striatin, Protein Phosphatase 2 Regulatory Subunit B'''Alpha, Striatin Calmodulin Binding Protein, Striatin Calmodulin-Binding Protein, PPP2R6A, SG2NA, STRN1, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
;
238
;
4233
;
6801
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK positive (74)
EGFR expression (46)
EGFR overexpression (34)
MET overexpression (32)
MET expression (12)
EGFR positive (8)
MET positive (8)
EGFR negative (6)
EGFR negative + ALK negative (4)
ALK negative (4)
EGFR expression + ALK positive (3)
EGFRVIII expression + PTEN expression (3)
EGFRvIII expression (3)
EGFR expression + MET expression (2)
EGFR overexpression + HER-2 overexpression (2)
MMP17 expression + EGFR expression + RB1 expression (2)
MUC1 expression + EGFR expression (2)
TROP2 expression + EGFR expression (2)
MET overexpression + KDR overexpression (2)
MET overexpression + SYK overexpression (2)
TPBG expression + MET expression (2)
EGFR expression + HER-2 expression (1)
EGFR underexpression (1)
EGFRVIII overexpression (1)
EPHA2 overexpression + EGFR overexpression (1)
GPC3 positive + EGFR expression (1)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
FGFR overexpression + MET overexpression (1)
MET expression + HER-2 expression (1)
MET overexpression + HER-2 overexpression (1)
MET overexpression + MUC5B overexpression (1)
MET underexpression (1)
DRD2 expression + EGFR overexpression (0)
YAP1 overexpression + EGFR overexpression (0)
PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)
ALK positive (74)
EGFR expression (46)
EGFR overexpression (34)
MET overexpression (32)
MET expression (12)
EGFR positive (8)
MET positive (8)
EGFR negative (6)
EGFR negative + ALK negative (4)
ALK negative (4)
EGFR expression + ALK positive (3)
EGFRVIII expression + PTEN expression (3)
EGFRvIII expression (3)
EGFR expression + MET expression (2)
EGFR overexpression + HER-2 overexpression (2)
MMP17 expression + EGFR expression + RB1 expression (2)
MUC1 expression + EGFR expression (2)
TROP2 expression + EGFR expression (2)
MET overexpression + KDR overexpression (2)
MET overexpression + SYK overexpression (2)
TPBG expression + MET expression (2)
EGFR expression + HER-2 expression (1)
EGFR underexpression (1)
EGFRVIII overexpression (1)
EPHA2 overexpression + EGFR overexpression (1)
GPC3 positive + EGFR expression (1)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
FGFR overexpression + MET overexpression (1)
MET expression + HER-2 expression (1)
MET overexpression + HER-2 overexpression (1)
MET overexpression + MUC5B overexpression (1)
MET underexpression (1)
DRD2 expression + EGFR overexpression (0)
YAP1 overexpression + EGFR overexpression (0)
PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification
Non Small Cell Lung Cancer
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification
Non Small Cell Lung Cancer
osimertinib
Resistant: C4 – Case Studies
osimertinib
Resistant
:
C4
osimertinib
Resistant: C4 – Case Studies
osimertinib
Resistant
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.